Proficio Capital Partners LLC Buys Shares of 31,492 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Proficio Capital Partners LLC acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,492 shares of the biotechnology company's stock, valued at approximately $3,829,000.

Several other large investors also recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its stake in Sarepta Therapeutics by 16.9% during the third quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company's stock worth $134,000 after acquiring an additional 155 shares in the last quarter. First Trust Direct Indexing L.P. boosted its stake in Sarepta Therapeutics by 26.4% during the third quarter. First Trust Direct Indexing L.P. now owns 1,635 shares of the biotechnology company's stock worth $204,000 after acquiring an additional 341 shares in the last quarter. US Bancorp DE boosted its stake in Sarepta Therapeutics by 4.3% during the third quarter. US Bancorp DE now owns 6,549 shares of the biotechnology company's stock worth $818,000 after acquiring an additional 271 shares in the last quarter. QRG Capital Management Inc. bought a new position in Sarepta Therapeutics during the third quarter worth $246,000. Finally, AlphaCentric Advisors LLC boosted its stake in Sarepta Therapeutics by 140.0% during the third quarter. AlphaCentric Advisors LLC now owns 18,000 shares of the biotechnology company's stock worth $2,248,000 after acquiring an additional 10,500 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on SRPT shares. StockNews.com lowered shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. HC Wainwright reaffirmed a "sell" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Royal Bank of Canada dropped their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $170.41.

Remove Ads

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $2.53 during trading hours on Friday, reaching $103.03. 1,160,008 shares of the company were exchanged, compared to its average volume of 906,964. Sarepta Therapeutics, Inc. has a 1 year low of $99.50 and a 1 year high of $173.25. The business's 50 day simple moving average is $114.48 and its 200-day simple moving average is $121.80. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $10.00 billion, a P/E ratio of 82.42 and a beta of 0.79.

Insider Transactions at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.